TP 53 aberrations in chronic lymphocytic leukemia an
TP 53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics by Elias Campo, Florence Cymbalista, Paolo Ghia, Ulrich Jäger, Sarka Pospisilova, Richard Rosenquist, Anna Schuh, and Stephan Stilgenbauer haematol Volume 103(12): 1956 -1968 November 30, 2018 © 2018 by Ferrata Storti Foundation
Overview of genetic complexity in chronic lymphocytic leukemia. Elias Campo et al. Haematologica 2018; 103: 1956 -1968 © 2018 by Ferrata Storti Foundation
Loss of wildtype (wt) p 53 function in chronic lymphocytic leukemia can occur as a result of del(17 p) and/or TP 53 mutations. 12, 28, 29, 31, 33 The most common cause of TP 53 aberrations is the result of a combination of TP 53 mutation and del(17 p), which accounts. . . Elias Campo et al. Haematologica 2018; 103: 1956 -1968 © 2018 by Ferrata Storti Foundation
TP 53 gene organization and distribution of mutations by codon. 63, 121, 122 The TP 53 gene is located at the p 13. 1 locus on the short arm of chromosome 17 and comprises 11 exon sequences that encode for the p 53 protein. Elias Campo et al. Haematologica 2018; 103: 1956 -1968 © 2018 by Ferrata Storti Foundation
An example of possible clonal evolution scenarios across the course of disease in chronic lymphocytic leukemia. 28, 50 Genomic diversification of CLL occurs through sequential acquisition of gene mutations, represented by clones of different colors. Elias Campo et al. Haematologica 2018; 103: 1956 -1968 © 2018 by Ferrata Storti Foundation
Comparison of methods for the detection of TP 53 aberrations. Elias Campo et al. Haematologica 2018; 103: 1956 -1968 © 2018 by Ferrata Storti Foundation
Progression-free and overall survival according to TP 53 status in the CLL 8 study. 10 Republished with permission from The American Society of Hematology, from: Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL 8 trial. Elias Campo et al. Haematologica 2018; 103: 1956 -1968 © 2018 by Ferrata Storti Foundation
Overview of clinical evidence from phase 2/3 trials for novel treatments in patients with TP 53 aberrations. Elias Campo et al. Haematologica 2018; 103: 1956 -1968 © 2018 by Ferrata Storti Foundation
- Slides: 8